Eleven Therapeutics
Next Generation of RNA Therapeutics
StartupEleven Therapeutics is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2020. Next Generation of RNA Therapeutics. The company has raised a total of $25.9M across 3 funding rounds, currently at the Seed stage. Eleven Therapeutics was founded by Prof. Yaniv Erlich, Prof. Greg Hannon, Shaul Ilan. Key investors include NFX Capital, Harel Insurance & Finance, Entrée Capital. The company has 11-50 employees. Core technologies: Artificial Intelligence.
With $25.9M in total funding, Eleven Therapeutics is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees11-50
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$22M
- NFX Capital
- Harel Insurance & Finance
- Entrée CapitalLead
Prof. Yaniv ErlichCo-founder & CEO
Prof. Greg HannonCo-founder & Director of Cancer Research UK, University of Cambridge
Shaul IlanCo-founder, COO & Business Development
6 articles covered by sources including www.prnewswire.com,
www.businesskorea.co.kr,
www.pharmaceutical-technology.com,
www.calcalistech.com,
www.finsmes.com.
What does Eleven Therapeutics do?
Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation. The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.
How much funding has Eleven Therapeutics raised?
Eleven Therapeutics has raised $25.9M in total funding across 3 rounds. The company is currently at the Seed stage. Key investors include NFX Capital, Harel Insurance & Finance, Entrée Capital.
Who founded Eleven Therapeutics?
Eleven Therapeutics was founded in 2020 by Prof. Yaniv Erlich (Co-founder & CEO), Prof. Greg Hannon (Co-founder & Director of Cancer Research UK, University of Cambridge), Shaul Ilan (Co-founder, COO & Business Development).
What sector is Eleven Therapeutics in?
Eleven Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.
Where is Eleven Therapeutics located?
Eleven Therapeutics is based in Ben Yehuda Street 99, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.